This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article, five key skills for pharmacy residents are identified and discussed. Authored by:Asma Alamri, Pharm.D. &Huda Almalki, Pharm.D. Post-Graduate Year-1Pharmacy Residents, Taif Health Cluster, Saudi Arabia Mentored by: Sameer Alzaidi, Pharm.D., BCPS, BCIDP, AAHIVP System-Wide Post-Graduate Year-1Pharmacy Residency Program Director, Taif Health Cluster, Saudi Arabia UNDER CONSTRUCTION Article Posted January 2024 According to the American College of Clinical Pharmacy (ACCP a reside
Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professionals mind as they start the new year.
After nearly a decade of machine learning innovation in the drug industry, the Food and Drug Administration Monday published its first draft guidance on the use of artificial intelligence in the development of drugs and biological products. The guidance comes as drug regulatory submissions citing AI have increased exponentially. In an interview with STAT in October, the FDA’s Tala Fakhouri, who co-leads the Center for Drug Evaluation and Research’s AI Council, said the agency has r
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The US Food and Drug Administration (FDA) has for the first time, issued draft guidance on using artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product. The guidelines address the safety, effectiveness or quality of these medicines. FDA has previously published a discussion paper that was produced to inform its guidance on AI in pharmaceutical drug development.
In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money. Most drug companies have venture funds, which they use both to make investments and to scout out potentially important scientific and technological trends. But it is unusual for a drug giant to co-manage a fund with an existing venture capital firm, or for a venture capital fund to source its capital from a
145
145
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money. Most drug companies have venture funds, which they use both to make investments and to scout out potentially important scientific and technological trends. But it is unusual for a drug giant to co-manage a fund with an existing venture capital firm, or for a venture capital fund to source its capital from a
Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions The Danish drug company Novo Nordisk provided hundreds of thousands of pounds worth of sponsorship to pharmacies including Boots and Lloyds as it sought to boost sales of its slimming drugs in Britain, the Observer can reveal.
Why could we see more deal-making at this year’s J. P. Morgan Healthcare conference? Why are investors concerned about a slowdown in U.S. biotech innovation? And what are the hosts’ New Year’s resolutions? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Semaglutide is an active ingredient in a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. These prescription drugs are used to treat Type 2 diabetes, promote weight loss , and reduce the risk of heart disease. Common brand-name drugs that contain this ingredient include Ozempic , Wegovy , and Rybelsus all manufactured by Novo Nordisk, a Danish pharmaceutical company.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we do plan to promenade with the official mascots, catch up on our reading and hold a listening party with Mrs. Pharmalot, where the rotation will likely include this , this , this , this and this.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Gabapentin is a prescription medication used to treat nerve pain and epilepsy. Although gabapentin is an anticonvulsant , its often used off-label to treat restless legs syndrome (RLS) and other nerve conditions or neuropathic pain. It can also treat postherpetic neuralgia, a type of pain that happens after having shingles. Brand names include Neurontin and Gralise.
Seven UnitedHealth Group shareholders are calling on the health care conglomerate to produce a report on how often its policies lead to denied or delayed care, and the effects on patients and the economy. The proposal , which could go up for a vote by UnitedHealth’s investors at the company’s annual meeting later this year, comes as the company is under tremendous public scrutiny for tactics such as prior authorization and care denials.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
As of January 10, there are 5 major fires across a combined 36,560 acresPalisades, Eaton, Kenneth, Hurst, and Lidiaand the 2 largest fires are a combined 11% contained.
The acceleration of artificial intelligence is arriving just in time for the biopharmaceutical industry. The global demand for innovative, effective treatments is growing faster than ever as the world’s largest drugmakers face intensifying regulatory, pricing, and political pressure. In this challenging environment, traditional industry processes must simply move faster.
Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for its novel contractile agents. The round was co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures. AnaCardios AC01 is a calcium sensitising inotrope, selective oral ghrelin receptor (GHSR1a) agonist in development to improve contractility in […] The post AnaCardio raises $19m in funding round for heart failure candidate appeared first on Phar
The advent of the first generic GLP-1 drugs could help Medicare negotiate a lower price for the highly sought after diabetes and obesity medication semaglutide , according to experts familiar with the price-negotiation program and STAT’s review of documents from the first round of negotiations.
Biotech company NMD Pharma has announced that the US Food and Drug Association (FDA) have granted its Charcot-Marie-Tooth (CMT) disease treatment NMD670 orphan drug designation (ODD). NMD670 was previously granted ODD by the FDA for generalised myasthenia gravis in September 2022. NMD670 is a small molecule inhibitor of the skeletal muscle-specific chloride ion channel CIC-1. […] The post NMD Pharmas Charcot-Marie-Tooth disease treatment granted ODD by FDA appeared first on Pharmafile.
Top of the morning to you, and a fine one it is, although we concede this may depend on your tolerance for frigid temperatures. Nonetheless, blue skies and a shiny sun are enveloping the Pharmalot campus, where the official mascots are hunting wildlife and we are engaged in the usual rituals — firing up the coffee kettle in order to brew a cup of stimulation (the choice today, hazelnut mocha) and foraging for items of interest.
Hippocratic AI is kicking off 2025 with a bang. The startup, which is building a large language model specifically for healthcare use cases, banked a $141 million series B financing round only nine months after its series A round.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
334 
Let's personalize your content